Related Experiment Video
Updated: Aug 2, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Gene expression profiling of renal medullary carcinoma: potential clinical relevance
Ximing J Yang1, Jun Sugimura, Maria S Tretiakova
1Department of Pathology, The University of Chicago, Chicago, Illinois, USA.
Background:
Renal medullary carcinoma is a rare kidney tumor with highly aggressive behavior. This tumor occurs exclusively in young patients with sickle cell trait or disease. To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established.
Methods:
The authors analyzed the gene expression profiles of 2 renal medullary carcinomas from patients with sickle cell trait using microarrays containing 21,632 cyclic DNA (cDNA) clones and compared them with the gene expression profiles of 64 renal tumors.
Results:
Based on global gene clustering with 3583 selected cDNAs, the authors found a distinct molecular signature of renal medullary carcinoma, which clustered closely with urothelial (transitional cell) carcinoma of the renal pelvis, rather than renal cell carcinoma (RCC). This finding of a significant difference in the gene expression patterns of renal medullary carcinoma compared with RCC suggests that this tumor should not be treated as a conventional RCC but, rather, as a special malignancy. This study also identified genes/proteins that may serve as biomarkers for renal medullary carcinoma or as potential targets of novel therapies. In addition, comparative genomic microarray analysis allowed the authors to predict the lack of chromosomal imbalances in this tumor.
Conclusions:
To the authors' knowledge, the current study is the first molecular profiling of renal medullary carcinoma, a rare but highly aggressive kidney carcinoma. The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions.
Insights
Renal medullary carcinoma, a rare aggressive kidney tumor in sickle cell patients, has a distinct molecular profile. This finding suggests it should be treated differently from conventional kidney cancer, paving the way for new therapies.
Area of Science:
- Oncology
- Molecular Genetics
- Genomics
Background:
- Renal medullary carcinoma (RMC) is a rare, aggressive kidney tumor predominantly affecting young individuals with sickle cell trait or disease.
- The molecular genetics and effective therapeutic strategies for RMC remain largely unknown.
Observation:
- Gene expression profiling was performed on two RMC samples from patients with sickle cell trait.
- Expression data was compared against a panel of 64 other renal tumors.
Findings:
- RMC exhibits a distinct molecular signature that closely resembles urothelial (transitional cell) carcinoma, not renal cell carcinoma (RCC).
- This molecular classification indicates RMC should be managed as a distinct malignancy, separate from conventional RCC.
- Specific genes and proteins were identified as potential biomarkers and therapeutic targets for RMC.
- Comparative genomic analysis suggests a lack of chromosomal imbalances in RMC.
Implications:
- This study represents the first molecular profiling of RMC, offering insights into its unique pathways.
- Identified molecular features may lead to novel diagnostic markers and effective therapeutic interventions for this aggressive cancer.
- The distinct classification of RMC has significant implications for treatment strategies and clinical management.
